Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chani Field"'
Autor:
Chani Field, Susan Branford, J. Graeme Hodgson, Timothy P. Hughes, Bronte A. Jamison, Victor M. Rivera, Stephanie Lustgarten, Alexandra L. Yeoman, David T Yeung, Haley Altamura, Wendy T Parker
Publikováno v:
Blood. 127:1870-1880
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4b68d3ac6b5526d8b996d5da9603bb
https://doi.org/10.1182/blood-2015-09-666214
https://doi.org/10.1182/blood-2015-09-666214
Autor:
John F. Seymour, Cassandra Slader, Anthony K. Mills, Susan Branford, Phuong Dang, Junia V. Melo, Timothy P. Hughes, Robin Filshie, Chani Field, Christopher Arthur, Andrew Grigg, Paul A. Bartley, David M. Ross, Anthony P. Schwarer
Publikováno v:
Leukemia. 24:1719-1724
Around 40-50% of patients with chronic myeloid leukemia (CML) who achieve a stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson leukemia gene human homolog 1 (BCR-ABL1) mRNA) on imatinib can stop therapy and remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6670010bf4c4c04719623529e87abd55
https://doi.org/10.1038/leu.2010.185
https://doi.org/10.1038/leu.2010.185
Autor:
Brad Sullivan, John V. Reynolds, Haley Altamura, Alexandra L. Yeoman, Jasmina Georgievski, John F. Seymour, Mark P. Hertzberg, David T Yeung, Chani Field, Timothy P. Hughes, Bronte A. Jamison, Stuart Phillis, Jodi Prime, David M. Ross, Nancy Briggs, Susan Branford
Publikováno v:
Blood. 121(19)
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML) can maintain remission after discontinuation of imatinib. A prerequisite is stable, undetectable BCR-ABL1. It is not known how many patients achieve this response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::708466f073d74972a3e73879b1c18eba
https://pubmed.ncbi.nlm.nih.gov/23515925
https://pubmed.ncbi.nlm.nih.gov/23515925
Autor:
Chani Field, Mithat Gonen, Susan Branford, Hagop M. Kantarjian, Jorge E. Cortes, Franziska Michor, Timothy P. Hughes, Alfonso Quintás-Cardama, Min Tang
Publikováno v:
Blood. 118(6)
Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitors (TKIs) imatinib mesylate and nilotinib represents a successful application of molecularly targeted anticancer therapy. However, the effect of TKIs on leukemic stem cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eee1911af6317e3fc347d985af07db1
https://pubmed.ncbi.nlm.nih.gov/21653938
https://pubmed.ncbi.nlm.nih.gov/21653938
Autor:
Wendy T Parker, Alexandra L Yeoman, Haley Altamura, Nicola Roberts, David T Yeung, Bronte A Jamison, Chani Field, Stephanie Lustgarten, Graeme Hodgson, Victor M. Rivera, Timothy P. Hughes, Susan Branford
Publikováno v:
Blood. 122:651-651
Background BCR-ABL1 mutations (muts) frequently cause resistance to tyrosine kinase inhibitors (TKIs) in CML. T315I, the most common mut, confers resistance to 1st and 2nd generation TKIs. In vitro studies suggest that all common individual muts are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ad107360b3e9c021f840edabdfac74f
https://doi.org/10.1182/blood.v122.21.651.651
https://doi.org/10.1182/blood.v122.21.651.651
Autor:
David T Yeung, Jodi Prime, Brad Sullivan, Alexandra L. Yeoman, Susan Branford, Jasmina Georgievski, David M. Ross, Chani Field, Stuart Phillis, Timothy P. Hughes, Bronte A. Jamison, Haley Altamura
Publikováno v:
Blood. 120:165-165
Abstract 165 Introduction. The opportunity to discontinue kinase inhibitor therapy while maintaining a deep remission is desirable for many CML patients. Despite good responses to imatinib for most patients, treatment related side effects remain prob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42bb63a4948448421ce0e2dbc5b7739c
https://doi.org/10.1182/blood.v120.21.165.165
https://doi.org/10.1182/blood.v120.21.165.165